Telix Pharmaceuticals Stock

Telix Pharmaceuticals EBIT per Employee

Delisted·Jun 19, 2026

The EBIT per Employee of Telix Pharmaceuticals (TLX.AX) as of Aug 22, 2026 is 515,083.33 USD. In the previous year, EBIT per Employee was 909,716.67 USD — a change of -43.38% (lower).

EBIT per Employee

515,083.33USD

YoY

-43.38%

Last updated:

EBIT per Employee of Telix Pharmaceuticals is 2026 515,083.33 USD. EBIT per Employee of Telix Pharmaceuticals was 2025 909,716.67 USD. It decreases by -43.38% lower compared to the previous year.
Access this data via the Eulerpool API

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

EBIT per Employee of Telix Pharmaceuticals is 515,083.33 USD in 2026.

EBIT per Employee of Telix Pharmaceuticals changed from 909,716.67 USD to 515,083.33 USD, representing a -43.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

Workforce — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals